Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Jason John LukeDiwakar DavarRobert H AndtbackaNina BhardwajJoshua D BrodyJason A ChesneyRobert CoffinThierry de BaereTanja D de GruijlMatthew FuryGregory GoldmacherKevin J HarringtonHoward KaufmanCiara M KellyAnuradha D KhilnaniKe LiuSherene LoiGeorgina V LongIgnacio Melero BermejoMark Ross MiddletonBart NeynsDavid James PinatoRahul A ShethStephen B SolomonPhilippe SzaparyAurélien MarabellePublished in: Journal for immunotherapy of cancer (2024)
The SITC Intratumoral Immunotherapy Clinical Trials Expert Panel has identified key considerations for the design and implementation of studies that have the greatest potential to capture the effect of intratumorally delivered immunotherapies. With more effective and standardized trial designs, the potential of intratumoral immunotherapy can be realized and lead to regulatory approvals that will extend the benefit of these local treatments to the patients who need them the most.